Bruce Strober, MD/PhD, FAAD
About
Research
Publications
2024
Risk of Developing Inflammatory Arthritis in Psoriasis Patients Initiating Treatment With Biologics: A Population Based Analysis
Strober B, Soliman A, Li C, Patel M, Unigwe I, Gisondi P. Risk of Developing Inflammatory Arthritis in Psoriasis Patients Initiating Treatment With Biologics: A Population Based Analysis. Journal Of The American Academy Of Dermatology 2024 PMID: 39197499, DOI: 10.1016/j.jaad.2024.06.106.Peer-Reviewed Original ResearchIL-23 inhibitorsDevelopment of inflammatory arthritisIL-23IL-17Inflammatory arthritisPsO patientsTNF inhibitorsMultivariate Cox proportional hazards modelDiagnosis of inflammatory arthritisPatients initiate treatmentCox proportional hazards modelsData Mart DatabaseAdjusted hazard ratiosProportional hazards modelIL-12/23Hazard ratioLow riskPatientsProtopathic biasBaseline diagnosisIncidence rateHazards modelArthritisTNFEffect of biological treatmentLB946 Spesolimab controls chronic inflammation in GPP
Krueger J, Gudjonsson J, Morita A, Lebwohl M, Warren R, Mostaghimi A, Langley R, Tang M, Visvanathan S, Thoma C, Strober B. LB946 Spesolimab controls chronic inflammation in GPP. Journal Of Investigative Dermatology 2024, 144: s165. DOI: 10.1016/j.jid.2024.06.1119.Peer-Reviewed Original ResearchBimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials
Gordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, López Pinto J, Gisondi P. Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s404. DOI: 10.25251/skin.8.supp.404.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsSevere plaque psoriasisOpen-label extensionPlaque psoriasisOral candidiasisPatient yrModerate to severe plaque psoriasisUpper respiratory tract infectionLong-term safety of treatmentRespiratory tract infectionsNext scheduled visitYear of treatmentSafety of treatmentLong-term safetySafety findingsTract infectionsLong-term managementBimekizumabSafety profileAdverse eventsPooled analysisClinical trialsQ8WSafety dataPsoriasisSpesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial
Gottlieb A, Strober B, Kokolakis G, Merola J, Zheng M, Langley R, Tang M, Hofmann P, Thoma C, Warren R. Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s409. DOI: 10.25251/skin.8.supp.409.Peer-Reviewed Original ResearchGeneralized pustular psoriasisDermatology Life Quality IndexDermatology Life Quality Index scoresGeneralized pustular psoriasis flaresPustular psoriasisVisits up to weekWeek 4Results Baseline characteristicsLength of diseaseLife Quality IndexLife-threatening diseasePlacebo groupHigh-doseSkin pustulesBaseline characteristicsSpesolimabFlare preventionPlaceboDLQI scoreQuality of lifePatientsWeeksPsoriasisScoresDiseaseDeucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s406. DOI: 10.25251/skin.8.supp.406.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsSafety signalsPatientsContinuous treatmentResponse rateIncidence rateParent trialPsoriasisAllosteric TYK2 inhibitorDeucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Strober B, Imafuku S, Paul C, Gooderham M, Spelman L, Seo S, Passeron T, Hoyt K, Colombo M, Banerjee S, Augustin M, Stein Gold L, Alexis A, Thaci D, Lebwohl M, Issa N, Cameron M. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s407. DOI: 10.25251/skin.8.supp.407.Peer-Reviewed Original ResearchLong-term extensionModerate to severe plaque psoriasisSevere plaque psoriasisPlaque psoriasisLong-term extension trialsResponse rateModified nonresponder imputationMaintenance of responseYears of continuous treatmentPhase 3 trialLong-term efficacyNonresponder imputationPrimary endpointPsoriasis AreaResponse assessmentClinical efficacyDeucravacitinibPASISafety signalsTreatment durabilityPatientsContinuous treatmentPsoriasisLong-term effectsParent trialDeucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Korman N, Warren R, Bagel J, Armstrong A, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli L, Kisa R, Banerjee S, Blauvelt A. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. Journal Of Dermatological Treatment 2024, 35: 2371045. PMID: 38945549, DOI: 10.1080/09546634.2024.2371045.Peer-Reviewed Original ResearchConceptsMaintenance of responseModerate to severe plaque psoriasisOnset of actionSevere plaque psoriasisPlaque psoriasisApremilast-treated patientsEfficacy measuresOral placeboClinical responseCoprimary endpointsDeucravacitinibPsoriasis trialsWeek 8PlaceboPASIPatientsWeek 1WeeksEfficacyPsoriasisSPGABaselineSignificant improvementTrialsApremilastP101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study
Wang Z, Yang M, Chao J, Martins B, Chuang C, Shumel B, Sierka D, Carboni M, Strober B. P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study. British Journal Of Dermatology 2024, 191: i63-i64. DOI: 10.1093/bjd/ljae090.128.Peer-Reviewed Original ResearchAtopic dermatitisEpisodes of itchingTreatment satisfactionMonth 1Disease controlClinical practiceProportion of patientsPatient survey studyPercentage of patientsSustained improvementFollow-up resultsPrescribed dupilumabGeneralized estimating equationsQuality of lifePatient support programmeSingle-armDupilumabSkin symptomsBaseline surveyPatientsSupport programmesPatient satisfactionPractice guidelinesStatistical significanceMonthsAssociation Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data
Strober B, Soliman A, Truong B, Patel M, Barqawi Y, Gisondi P. Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data. American Journal Of Clinical Dermatology 2024, 25: 853-856. PMID: 38937425, PMCID: PMC11358220, DOI: 10.1007/s40257-024-00877-w.Peer-Reviewed Original ResearchSix-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 11: 451-464. PMID: 38914857, PMCID: PMC11365873, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world study